Loudon Investment Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.69M Sell
35,308
-9,425
-21% -$405K 0.83% 33
2026
Q1
$1.64M Sell
44,733
-5,450
-11% -$258K 0.88% 34
2025
Q4
$2.55M Sell
50,183
-5,198
-9% -$266K 1.33% 28
2025
Q3
$3.07M Buy
55,381
+17,710
+47% +$1.04M 1.61% 23
2025
Q2
$2.6M Buy
+37,671
New +$2.56M 1.44% 24

Other funds holding NVO

Loudon Investment Management's NVO Position: Q2 2026 in Review

Loudon Investment Management reduced its Novo Nordisk (NVO) stake by 21% in Q2 2026, selling an estimated $405K and leaving 35,308 shares worth $1.69M. The position accounts for 0.83% of the portfolio, ranked #33.

Loudon Investment Management first reported a position in NVO in Q2 2025 and has held it in 5 quarters since. The position peaked at $3.07M in Q3 2025. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Loudon Investment Management held 35,308 shares of Novo Nordisk worth $1.69M as of Q2 2026.
  • Loudon Investment Management sold 9,425 Novo Nordisk shares in Q2 2026, an estimated $405K.
  • Novo Nordisk made up 0.83% of Loudon Investment Management's portfolio in Q2 2026, its #33 holding.
  • Loudon Investment Management first reported a position in Novo Nordisk in Q2 2025 and has held it in 5 quarters since.
  • Loudon Investment Management's Novo Nordisk position peaked at $3.07M in Q3 2025.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Loudon Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.